Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (10): 1151-1159.doi: 10.12092/j.issn.1009-2501.2020.10.011

Previous Articles     Next Articles

Advances in the evaluation of intra-tumoral delivery of antitumor drugs

LIU Yan 1, LIU Jiali 1, JIA Yuanwei 2, ZHOU Fang 1, WANG Guangji 1, ZHANG Jingwei 1   

  1. 1 Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; 2 Drug Clinical Evaluation Center, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China
  • Received:2020-04-14 Revised:2020-07-14 Online:2020-10-26 Published:2020-11-03

Abstract: Tumor tissue is highly heterogeneous and complex in structure. Numerous barriers make it difficult for anti-tumor drugs to reach the center of the tumor tissue, which affects the efficacy. Currently, various strategies to improve intra-tumoral drug delivery are emerging in an endless stream, but the clinical conversion efficiency is low. Hence, it is essential to improve the early evaluation system of intra-tumoral drug delivery. Reasonable evaluation of intra-tumoral drug delivery can rely on three-dimensional cell models, in-vivo imaging technology and appropriate mathematical model to comprehensively reveal the drug delivery process in tumor tissues, predict and screen various influencing factors, and feedback to guide the optimization of intra-tumoral delivery of drugs. This article reviews the evaluation methods of intra-tumoral delivery of anti-tumor drugs, aiming to evaluate the transport of anti-tumor drugs in tumor tissues more accurately and reasonably, and to provide reference and ideas for the synthesis, preparation design, drug combination and optimization of clinical drug regimen of anti-tumor drugs.

Key words: tumor, drug delivery, three-dimensional cell model, in vivo imaging, mathematical model

CLC Number: